Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 4;13(3):e0239724.
doi: 10.1128/spectrum.02397-24. Epub 2025 Jan 16.

Macrolide resistance due to erm(55)

Affiliations

Macrolide resistance due to erm(55)

David C Alexander et al. Microbiol Spectr. .

Abstract

Antimicrobial resistance (AMR) is a global threat. The identification and characterization of novel resistance genes is integral to AMR surveillance. The erm(55) gene was originally identified through whole genome sequencing of macrolide-resistant strains of Mycobacterium chelonae. The gene was annotated as a ribosomal methyltransferase, but its role as a determinant of macrolide resistance was not formally demonstrated. Three erm(55) alleles have now been documented. The plasmid-borne erm(55)P, the transposon-associated erm(55)T, and the chromosomal encoded erm(55)C exhibit ≈82% amino acid sequence identity. Here, we confirm that, when expressed from plasmids in a macrolide-susceptible strain of Escherichia coli, all three erm(55) variants confer resistance to azithromycin and clarithromycin.

Importance: Macrolide antibiotics are often the only oral treatment option for infections with rapidly growing mycobacteria such as Mycobacterium abscessus and Mycobacterium chelonae. We previously identified three variants of a newly predicted macrolide resistance gene, erm(55), in M. chelonae, including the first case of a plasmid-mediated macrolide resistance in mycobacteria. The present study provides experimental evidence that the three erm(55) variants confer macrolide resistance and that each variant is unique in the degree to which it reduces susceptibility to clinically relevant macrolides.

Keywords: Mycobacterium; antibiotic resistance; molecular biology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Dinos GP. 2017. The macrolide antibiotic renaissance. Br J Pharmacol 174:2967–2983. doi:10.1111/bph.13936 - DOI - PMC - PubMed
    1. Brown-Elliott BA, Nash KA, Wallace RJ Jr. 2012. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev 25:545–582. doi:10.1128/CMR.05030-11 - DOI - PMC - PubMed
    1. Koh WJ, Jeon K, Lee NY, Kim BJ, Kook YH, Lee SH, Park YK, Kim CK, Shin SJ, Huitt GA, Daley CL, Kwon OJ. 2011. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 183:405–410. doi:10.1164/rccm.201003-0395OC - DOI - PubMed
    1. Fyfe C, Grossman TH, Kerstein K, Sutcliffe J. 2016. Resistance to macrolide antibiotics in public health pathogens. Cold Spring Harb Perspect Med 6:a025395. doi:10.1101/cshperspect.a025395 - DOI - PMC - PubMed
    1. Roberts MC, Sutcliffe J, Courvalin P, Jensen LB, Rood J, Seppala H. 1999. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother 43:2823–2830. doi:10.1128/AAC.43.12.2823 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources